"The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!"
All of a sudden the market's perception of the value of a company is gospel?
I respectfully disagree with you (and others) belief that Ariad at a market cap of $735 million is over valued. Rida may not show efficacy in sarcoma (doubt it). I believe it will definitely show value in other indications in the near future. This story is 12 to 18 months away. If Pona turns out to be what I think it will, $735 will be a long way off in our rear view mirror. I have the time to wait.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.